Replies to post #136091 on Biotech Values

[goochbart]

Biomaven,

I really appreciate your viewpoints.

More attention is being given to cancer stem cell eradication, IMUC seems to be in the sweet spot with a low profile.

I am curious about your thoughts on IMUC, whose focus is on eliminating csc. The stock is less than 50 million cap and is funded (shot up today however). Its therapy drug 107 in phase 2 (over 100 have been quickly enrolled)appears best in class for gliablastomas, is a vaccine using dendtric cells (like DNDN) and 6 targeted antigens, and is inexpensive to produce and administer(unlike DNDN) They also have similar CSC targeted drugs for ovarian, etc. Is this stock undervalued?

[poorgradstudent]

hypoxia:

Speaking of hypoxia, is it just me or is fibrogen's HIF inhibitor moving very slowly? They had an update late last year but it feels like they've been in phase II forever.